Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Modeling the Entrepeñas Reservoir.
Wiese BU, Palancar MC, Aragón JM, Sánchez F, Gil R. Wiese BU, et al. Water Environ Res. 2006 Aug;78(8):781-91. doi: 10.2175/106143006x123940. Water Environ Res. 2006. PMID: 17059129
Outcomes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network.
Sanz A, Ayala R, Hernández G, Lopez N, Gil-Alos D, Gil R, Colmenares R, Carreño-Tarragona G, Sánchez-Pina J, Alonso RA, García-Barrio N, Pérez-Rey D, Meloni L, Calbacho M, Cruz-Rojo J, Pedrera-Jiménez M, Serrano-Balazote P, de la Cruz J, Martínez-López J. Sanz A, et al. Among authors: gil r, gil alos d. Blood Cancer J. 2022 Jun 24;12(6):94. doi: 10.1038/s41408-022-00692-8. Blood Cancer J. 2022. PMID: 35750670 Free PMC article. No abstract available.
A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease.
Olanow CW, Hauser RA, Burdick DJ, Dhall R, de Marcaida JA, Gil RA, Kreitzman DL, Elmer LW, McGarry A, Kieburtz K; P2B Study Group. Olanow CW, et al. Among authors: gil ra. Mov Disord. 2024 Feb;39(2):350-359. doi: 10.1002/mds.29642. Epub 2023 Oct 27. Mov Disord. 2024. PMID: 37886872 Clinical Trial.
Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies.
Rascol O, Tönges L, deVries T, Jaros M, Quartel A, Jacobs D; ALLAY-LID I and ALLAY-LID II study groups. Rascol O, et al. Parkinsonism Relat Disord. 2022 Mar;96:65-73. doi: 10.1016/j.parkreldis.2022.01.022. Epub 2022 Feb 8. Parkinsonism Relat Disord. 2022. PMID: 35227940 Free article. Clinical Trial.
62 results